Immunitrack ApS

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

Celentyx is a human immune system focused R&D and service company specialising in immuno-oncology, inflammation and autoimmunity in vitro assays using healthy donor and patient tissues and cells.

Celentyx’s unique ImmuKnowlogy™ platform allows rapid analysis of drug action on human immune cells - from healthy donors or patients with defined clinical disease. Drawing on the World-leading expertise of Celentyx personnel, which along with our strategic relationships with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research (at the Queen Elizabeth 'Super-hospital', Birmingham), enables the human immune system to be investigated at the highest levels of resolution.

Celentyx's ImmuKnowlogy™ services enable partners to quantify efficacy, elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.

Celentyx's Novel Clinical Indication Profiling™, which applies the powerful Immuno-Profiling™ platform to reprofile (repurpose) drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug indications.

Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas.

We provide bespoke pre-clinical/early discovery phase laboratory services to support academic groups, pharmaceutical and biotechnology companies in their R&D studies and biomarker research.

The Company
- Founded in 2015 and Privately owned
- Operating out of Biocity, Nottingham
- Experienced Management team with track record of delivering complex scientific projects and peer reviewed
international publications
- Completed over 40 successful scientific projects in collaboration with over 25 sponsors
- Links with leading UK Universities
- Fully serviced laboratory with Specialised personnel
- National and International partners

Our USP:
- Dynamic CRO offering specialist skills with over 30 years of combined experience
- Therapeutic area expertise
- Value for money
- Efficient time management, thanks to our streamlined structure
- Flexibility in operations to suit our client needs.
- Customised service and support focused on customer retention and satisfaction
- Logistics support

Our vision is 'Integrated scientific services; from experimental conception to project delivery'​.

Our mission is:
- To revolutionise drug discovery research by providing integrated, cost-effective laboratory services including assay design consultancy, logistics support, bespoke high quality assay development/validation and data analysis.
- To be a responsible and trusted laboratory-based CRO partner with Quality, Flexibility, Reliability and Customer support as our indispensable asset.

Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).

The innovative, first and best in class programmes are designed to activate only tumour-specific T cells in the tumour micro-environment and not outside it. This approach is expected to reduce the toxicities experienced with traditional immunotherapies and also to lead to the proliferation of tumour-specific T cells with a broad, long-lasting anti-tumour response.

Our lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific for PSMA-positive tumours. CB307’s unique format delivers highly potent tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA-positive cancer indications.

Crescendo’s pipeline is underpinned by its novel, patent-protected Humabody® platform, which generates fully human VH domains (Humabodies). Humabodies are matured in vivo in the absence of any light-chains and are robust and stable molecules. Humabody VH domains can be easily assembled into multi-specific formats which can access novel biology and deliver superior tumour accumulation and penetration compared to conventional monoclonal antibody-based approaches.

The Humabody platform has received third party validation through its strategic, multi-target collaboration in immuno-oncology, ADCs and CAR-Ts with Takeda, worth up to $790M, and from licensing its first programme for an inflammatory target to Zai Lab in 2018. In 2020 Crescendo entered into a Clinical Development Partnership with Cancer Research UK to progress CB213, a PD-1 x LAG-3 bispecific, into the clinic.

Crescendo is progressing novel Humabody®-based product opportunities, through in-house development and strategic collaborations as well as seeking strategic partners to develop novel Humabody therapeutics leveraging our in-house expertise and our pipeline of Humabody molecules.

Explicyte is a family brand of specialty preclinical services launched by ImmuSmol, a bordeaux-based company. The first brand, Explicyte Immune-Oncology offers preclinical contract research services in immuno-oncology.

Explicyte Immuno-Oncology currently offers to test innovative cancer immunotherapies in vivo, using syngeneic mouse tumor models treated with immune checkpoint inhibitors (eg. anti-CTLA-4 and anti-PD1/PD-L1 antibodies). In addition, Explicyte is setting up an in vitro platform for the identification and optimization of novel immunomodulators. Equipped with high-content analysis technologies, the platform focuses on live phenotypic screening in co-cultures of immune and cancer cells, as well as molecular cell-based assays for the assessment of immune checkpoint inhibitors.